IL5RA and Barrett esophagus: The main finding of this real-world study is that the anti-IL-5Rα biologic treatment determined a significant reduction in asthma exacerbations while improving asthma control and pulmonary function after 6 and 12 months of treatment, in patients with SEA with or without BE.